Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Clc3.0
Colchicine – Forschung
Überwiegend Mechanismus / Beobachtung
44 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Colchicine sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2013–2026 mit einer typischen Studiengröße von 1,049 Teilnehmenden.
Basierend auf 44 Studien · 17 Meta-Analysen · 9 RCTs · 115,205 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Cardiovascular eventsNiedrig dosiertes Colchicine reduzierte in randomisierten Studien schwerwiegende kardiovaskuläre Ereignisse bei koronarer Herzkrankheit und nach Myokardinfarkt · Monate bis Jahre
Überwiegend Mechanismus / Beobachtung21 Studien
Inflammation / inflammagingSenkt CRP und inflammasomgetriebene Signalwege · Wochen
Überwiegend Mechanismus / Beobachtung9 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung7 Studien
Aktives Forschungsgebiet
40 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
201320192026
1RCTn=262 · medium study2026
This randomized clinical trial found that, in patients with symptomatic knee OA and effusion-synovitis, diacerein (50 mg, twice daily) over 24 weeks resulted in no greater improvement in knee pain compared with placebo.
Aitken D et al. · JAMA internal medicine (2026)
Of 262 participants randomized (mean [SD] age, 54.9 [6.1] years; 147 [56.1%] female and 115 [43.9%] male), 231 (88.2%) completed the trial.
Compared with placebo, diacerein did not improve knee pain over 24 weeks (-19.9 mm [diacerein] vs -18.6 mm [placebo]; between-group mean difference, -1.3 mm; 95% CI, -9.8 to 7.3).
The most common adverse events were gastrointestinal symptoms, which occurred in 55 participants (41.7%) in the diacerein group and 33 (25.4%) in the placebo group, most commonly diarrhea (51 [38.6%] in the diacerein group vs 29 [22.3%] in the placebo group).
Conclusions In patients with recent myocardial infarction, the available evidence assessing the effect of colchicine, in addition to standard therapy, on MACE remains inconclusive over a median follow-up duration of 1 year.
Moiz A, Zolotarova T, Eisenberg MJ. · Journal of the American Heart Association (2026)
Count data were pooled using random-effects models with inverse variance weighting to estimate risk ratios (RRs) and 95% CIs.
Most participants (79%) were male, with mean ages ranging from 59 to 61 years.
At maximum follow-up, there was no statistically significant difference in MACE between colchicine and placebo (8.2% versus 9.3%; RR, 0.83 [95% CI, 0.66-1.04]).
Future research should focus on standardized extract formulations, dose-response relationships, and clinical trials to validate its therapeutic efficacy in humans.
Buakaew W, Thongsri Y, Mahikul W, Usuwanthim K. · Scientific reports (2026)
The systematic review demonstrated that C. hystrix significantly reduced NO production, TNF-α, and IL-6 levels (p < 0.05) compared with controls, indicating strong anti-inflammatory activity.
Findings from the meta-analysis revealed that the pooled effect estimate indicated a mean inhibition rate of the bovine serum albumin (BSA) degradation of 46.48% (95% CI: 28.66-64.31; p < 0.001), while the inhibitory effect of C. hystrix on TNF-α was 36.43% (95% CI: 1.18-71.68; p < 0.05).
However, substantial heterogeneity (I² > 80%) was observed, which was likely attributable to variations in experimental models, extract types, and dosages used across studies.
Further studies are required to identify a population(s) who stands to benefit most from this promising therapy.
Tucker B, Tucker WJ, Chung JS, Figtree GA, Keech A, Patel S. · European journal of preventive cardiology (2026)
Pooled estimates were calculated using a random-effects model and are presented as risk ratio [95% confidence interval (CI)]. 1624 articles were screened. 12 met inclusion criteria, yet one trial reported zero endpoint events in both arms.
Colchicine was associated with a 17% reduction in the incidence of MACE [0.83 (0.73, 0.95); P = 0.006] and 23% reduction in the incidence of eMACE [0.77 (0.63, 0.94); P = 0.01].
This reduction was driven by a lower rate of MI [0.78 (0.63, 0.95); P = 0.02] and coronary revascularisation [0.73 (0.55, 0.97); P = 0.03].
Conclusion Targeting inflammation, proteolysis, thrombosis, and vascular remodelling can attenuate progression of established small AAAs in mice, with anti-inflammatory therapy uniquely demonstrating protection against rupture.
Data indicates that rofecoxib increases the risk of alveolar osteitis in patients undergoing tooth extraction.
Isiordia-Espinoza MA et al. · Medicina oral, patologia oral y cirugia bucal (2026)
On the other hand, subgroup statistical analysis for selective COX-2 inhibitors suggested that rofecoxib elevated a patient's risk of developing alveolar osteitis (n=947, I2=0%, Z=2.52, OR=1.89, 95% CI=1.15 to 3.10, p=0.01) compared with placebo.
Data indicates that rofecoxib increases the risk of alveolar osteitis in patients undergoing tooth extraction.
Overall, colchicine seems to lower the risk of MACE but the results of the CLEAR trial have lowered certainty, while the findings highlight the feasibility and efficiency gains of using large language models in evidence synthesis workflows.
Teperikidis L, Boulmpou A, Chownk M, Jagdale R, Booz GW, Biondi-Zoccai G, Bhatt DL. · Journal of cardiovascular pharmacology (2026)
Colchicine significantly reduced MACE (risk ratio (RR) 0.75, 95% CI, 0.63-0.88) and MI (RR 0.82, 95% CI 0.70-0.96), though no significant effects were observed for stroke, cardiovascular mortality, or all-cause mortality.
This integration reduced researcher time by >70% while maintaining accuracy through human validation.
In addition to its clinical findings, this study illustrates the potential of ChatGPT to assist in systematic reviews and meta-analyses by automating screening, data extraction, bias assessment, and statistical code generation.
No clear difference in reported event risk between this type of drug and placebo was found, though it is not clear that this is conclusive.
Bukhari S, Leth MF, Laursen CCW, Larsen ME, Tornøe AS, Schou NK, Glad M, de la Fuente A, Jakobsen JC, Maagard M, Mathiesen O. · Acta anaesthesiologica Scandinavica (2026)
Meta-analysis showed no statistically significant difference between NSAID and placebo for risk of serious adverse events, RR 0.83; 95% CI, 0.61 to 1.14; p = 0.26; very low certainty of evidence.
Post hoc beta-binomial regression sensitivity analyses, including trials with zero events, indicated no difference in risks of serious adverse events between NSAID and placebo (OR 0.89; 95% CI, 0.76 to 1.06; p = 0.19).
Trial Sequential Analysis showed that insufficient information was obtained to confirm or reject a relative risk change of 25%.
In conclusion, the use of colchicine in patients with CAD reduces MACE without significantly increasing SAEs compared to control, although increasing gastrointestinal adverse events, without interaction by clinical presentation.
Laudani C, Bujak K, Occhipinti G, Rinaldi R, Imbesi A, Sanchez JS, Galli M, Abbate A, Ortega-Paz L, Capodanno D, Angiolillo DJ. · Clinical pharmacology and therapeutics (2026)
After literature search, 20 trials encompassing a total of 21,486 patients (65.4% ACS) were included.
Colchicine significantly reduced MACE (incidence rate ratio [IRR]: 0.70; 95% CI 0.55-0.87) without increasing risk for SAEs.
Colchicine also reduced MI (IRR 0.81; 95% CI 0.70-0.94) and any revascularization (IRR 0.71; 95% CI 0.51-0.99), while increasing the risk of gastrointestinal adverse events (IRR 1.68; 95% CI 1.23-2.28).
Benefits were observed with 0.5 mg daily over a median 28.6 months.ConclusionColchicine is associated with a reduction in major cardiovascular events in individuals with diabetes, with consistent long-term benefit at low doses without an increase in adverse effects.
Yasaratna NR, Wijekoon D, Tardif JC, Reid C. · Diabetes & vascular disease research (2026)
PROSPERO registration: CRD42024575366.ResultsFive RCTs were included, comprising 2977 participants with diabetes (1492 (50%) colchicine; 1485 (50%) placebo/usual care).
Colchicine significantly reduced MACE, HR 0.79 (95% CI 0.67-0.94, p = 0.006).
Subgroup analysis of diabetic versus non-diabetic participants yielded a similar effect, HR 0.75 (95% CI 0.67-0.83, p < 0.001).
Colchicine reduces MACE, MI, and revascularization in CAD patients, supporting its use for secondary prevention.
Ahmed M, Fahim MAA, Humayun M, Sajid B, Ahmad S, Asghar MS. · Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025)
Random-effects models were used to calculate risk ratios with 95% CIs.
The colchicine group was significantly associated with a lower rate of MACE compared to the control group (RR = 0.73, 95% CI = 0.59-0.92, p = 0.006; I² = 44%).
From the secondary outcomes, eMACE (RR = 0.66, 95% CI = 0.52-0.85; p = 0.001; I² = 73%), MI (RR = 0.82, 95% CI = 0.70-0.96, p = 0.01), and coronary revascularization (RR = 0.60, 95% CI = 0.41-0.87, p = 0.007) were found to be significantly lower in the colchicine group.
Long-term assessment is indeed to validate the current findings.
Nazmy A, Sobhy A, Elshahat A, Atta K, Murad MR, Ibrahim M, El-Shirbiny H, Ibrahim RA, Sayed MS, Gomaa M, Shaban AY, Naeem M, Abdelaziz A. · Current problems in cardiology (2025)
Low-dose colchicine showed a non-significant trend toward reducing MACE versus placebo (RR = 0.90, 95% CI: 0.80-1.01, p = 0.07; I² = 0%).
Hospital readmission was significantly reduced by 49% (OR = 0.51, 95% CI: 0.26-0.98, p = 0.04; number needed to treat [NNT] = 25).
Colchicine increased the risk of diarrhea (RR = 1.58, 95% CI: 1.06-2.36, p = 0.03; I² = 71%; number needed to harm [NNH] = 50) but showed no significant differences in all-cause mortality, CV mortality, myocardial infarction, stroke, or other GIT events.
Therefore, the results support the use of colchicine to reduce recurrent cardiovascular events.
Samuel M, Berry C, Dubé MP, Koenig W, López-Sendón J, Maggioni AP, Pinto FJ, Roubille F, Tardif JC. · European heart journal (2025)
Over a follow-up of 12-34 months, colchicine reduced the incidence of MACE compared with placebo [pooled hazard ratio .75, 95% confidence interval (CI) .56-.93].
No differences were detected for safety outcomes (P > .05 for all), including non-cardiovascular deaths (risk ratio 1.08, 95% CI .76-1.54).
The reduction in cardiovascular events among colchicine patients was driven by reductions in MIs, ischaemic strokes, and urgent coronary revascularizations (P < .05 for all).
Phenotype-based CRS populations should be studied in well-designed trials, bioavailability formulations should be optimized, and synergistic combinations should be systematically explored.
Cao C et al. · Frontiers in immunology (2026)
Chronic rhinosinusitis (CRS) is a condition with a significant healthcare and economic burden, with a prevalence of 12% in the West.
Bromelain and cineole have clinical evidence in favor of efficacy in acute sinusitis, and other compounds are showing emerging evidence.
The FOXP3-C5aR1-LIF axis is a mechanistic therapeutic target that is largely overlooked by the current biologics.
Future directions include refinement of targeted therapies, use of advanced molecular imaging, and mechanistic studies to better delineate the pathways linking stress, inflammation, and cardiovascular disease.
Hakimjavadi R et al. · The Canadian journal of cardiology (2026)
Future directions include refinement of targeted therapies, use of advanced molecular imaging, and mechanistic studies to better delineate the pathways linking stress, inflammation, and cardiovascular disease.
Published in The Canadian journal of cardiology (2026)
These recommendations, which were updated based on new evidence and expert opinion, provide guidance for all stakeholders involved in the management of patients with Behçet's syndrome to improve the quality of care of these patients.
Hatemi G et al. · Annals of the rheumatic diseases (2026)
These recommendations, which were updated based on new evidence and expert opinion, provide guidance for all stakeholders involved in the management of patients with Behçet's syndrome to improve the quality of care of these patients.
Published in Annals of the rheumatic diseases (2026)
Here, we describe the current status of investigations into inflammasomes, their role in GBM pathogenesis, and their potential as therapeutic targets.
Govindarajan V et al. · Journal of neuroinflammation (2026)
Inflammasomes are protein complexes responsible for initiation of pro-inflammatory cascades and a specialized form of regulated cell death known as pyroptosis in response to noxious cellular stimuli.
Inflammasomes play a critical role in several disease processes, including multiple sclerosis and traumatic brain injury.
However, their role in GBM pathogenesis and regulation in the tumor microenvironment remains poorly understood.
Medicinal Dendrobium represents a promising ethnopharmacological resource, exhibiting broad-spectrum anti-inflammatory effects through multi-target, multi-pathway, and multi-organ mechanisms.
Yang BQ et al. · Journal of ethnopharmacology (2026)
Medicinal Dendrobium represents a promising ethnopharmacological resource, exhibiting broad-spectrum anti-inflammatory effects through multi-target, multi-pathway, and multi-organ mechanisms.
By focusing on these priorities, research can further elucidate the systemic anti-inflammatory mechanisms of medicinal Dendrobium, thereby bridging its traditional use with contemporary precision medicine, and supporting integrated interventions for complex inflammatory diseases.